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SepsisSirtuins (SIRT1-7) areNAD+-dependent histone deacetylases (HDACs) that play an important role in the control of
metabolism and proliferation and the development of age-associated diseases like oncologic, cardiovascular and
neurodegenerative diseases. Cambinol was originally described as a compound inhibiting the activity of SIRT1
and SIRT2, with efﬁcient anti-tumor activity in vivo. Here, we studied the effects of cambinol on microbial
sensing by mouse and human immune cells and on host innate immune responses in vivo. Cambinol inhibited
the expression of cytokines (TNF, IL-1β, IL-6, IL-12p40, and IFN-γ), NO and CD40 by macrophages, dendritic
cells, splenocytes andwhole blood stimulatedwith a broad range of microbial and inﬂammasome stimuli. Sirtinol,
an inhibitor of SIRT1 and SIRT2 structurally related to cambinol, also decreasedmacrophage response to TLR stim-
ulation. On the contrary, selective inhibitors of SIRT1 (EX-527 and CHIC-35) and SIRT2 (AGK2 and AK-7) used
alone or in combination had no inhibitory effect, suggesting that cambinol and sirtinol act by targeting more
than just SIRT1 and SIRT2. Cambinol and sirtinol at anti-inﬂammatory concentrations also did not inhibit SIRT6 ac-
tivity in in vitro assay. At themolecular level, cambinol impaired stimulus-induced phosphorylation ofMAPKs and
upstreamMEKs. Goingwell alongwith its powerful anti-inﬂammatory activity, cambinol reduced TNF blood levels
and bacteremia and improved survival in preclinical models of endotoxic shock and septic shock. Altogether, our
data suggest that pharmacological inhibitors of sirtuins structurally related to cambinol may be of clinical interest
to treat inﬂammatory diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The innate immune system provides the ﬁrst line of defense
against microbial infections. Macrophages and dendritic cells
(DCs) use pattern-recognition receptors (PRRs) to sense molecular
structures broadly shared by microorganisms (collectively called
microbial-associated molecular patterns or MAMPs) such as LPS,
lipopeptides, peptydoglycans, glucans, ﬂagellin and nucleic acids.
PRRs include TLRs, NOD-like receptors (NLRs), C-type lectin recep-
tors, RIG-I like receptors and the cytosolic DNA sensors [1]. Recog-
nition of microbial ligands by PRRs triggers intracellular signaling
pathways, including the NF-κB, ERK1/2, p38 and JNK MAPK andc cells; BMDMs, bone marrow-
leotide 1826; DC, dendritic cell;
LPS, lipopolysaccharide; MKP,
umoniae Caroli; Pam3CSK4,
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l rights reserved.IFN-regulatory factor (IRF) signaling pathways [1]. These events control
the expression of cytokines and adhesion, major histocompatibility and
co-stimulatorymolecules that play a crucial role in the initiation, ampli-
ﬁcation and regulation of the inﬂammatory response and in the coordi-
nation of cellular and humoral responses aimed at the eradication or
containment of invasive pathogens [2].
There are eighteen histone deacetylases (HDACs) in mammals, the
“classical” Zn-dependent HDAC1-11, and the NAD+-dependent sirtuins
(SIRT) 1–7. HDACs are sub-grouped into class I (HDAC1, 2, 3, and 8),
class II (HDAC4-7, 9, 10), class III (SIRT1-7) and class IV (HDAC11)
[3–5]. HDACs catalyze the cleavage of acetyl groups from lysine resi-
dues. Deacetylation of histones by HDACs is associated with chromatin
compaction and gene repression. HDACs also target numerous non-
histones proteins, among which are tubulin, transcriptional regulators
and enzymes. Accordingly, HDACs affect numerous biological and path-
ological processes, and have been implicated in the pathogenesis of on-
cologic, metabolic, cardiovascular, neurodegenerative and autoimmune
diseases. Small compound inhibitors of classical HDACs are developed
as potent anticancer drugs with remarkable tumor speciﬁcity. Beside
their anticancer activity, inhibitors of classical HDACs exert powerful
immuno-modulatory and anti-inﬂammatory activities [5,6].
Sirtuins have been proposed to promote longevity in several organ-
isms, albeit this topic is of intense debates [7]. Sirtuins require NAD+ for
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Sirtuins have been implicated in age related pathologies including
metabolic, neurodegenerative, cardiovascular and oncologic dis-
eases [8–10]. The picture is not so clear concerning the inﬂuence
of sirtuins on immune responses. Indeed, both pro-inﬂammatory
and anti-inﬂammatory activities have been attributed to SIRT1 and
SIRT6 [11–22]. Pharmacological inhibitors of sirtuins are developed
for their potential curative usage in metabolic and oncologic dis-
eases. Most of sirtuin inhibitors available today target SIRT1, the
best characterized sirtuin, and SIRT2. Recently, cambinol was identi-
ﬁed as a β-naphthol compound that inhibits SIRT1 and SIRT2 with
similar IC50s [23]. Cambinol competes with substrate but not with
NAD+ binding to SIRT1 and SIRT2, which may explain its selectivity
and low toxicity. Interestingly, cambinol possesses antitumor activity
in vivo [23].
Considering that sirtuins share targetswith HDAC1-11, and consider-
ing that we and others have described the powerful anti-inﬂammatory
activity of inhibitors of classical HDACs in vitro and in vivo [6,24,25],
we questionedwhether the sirtuin inhibitor cambinolmodulates inﬂam-
matory and innate immune responses. Here, we report that cambinol,
but not selective SIRT1 and SIRT2 inhibitors, strongly affects the response
of macrophages and DCs to a large panel of pathogen- and danger-
associatedmolecular patterns. Cambinol inhibitsMEK activation thereby
impairing phosphorylation-induced MAPK signaling and immune gene
expression.Most importantly, cambinol protects animals fromendotoxic
and septic shock. Our data support the concept of cambinol-like pharma-
cological inhibitors as promising drugs to treat inﬂammatory diseases.
2. Materials and methods
2.1. Ethics statement
Animal experimentations were approved by the Ofﬁce Vétérinaire
du Canton de Vaud (authorizations n° 876.7 and 877.7) and performed
according to our institution guidelines.
2.2. Mice, cells and reagents
BALB/c mice (8–12 week females; Charles River Laboratories) were
housed under speciﬁc pathogen-free conditions. Bone marrow cells
were cultured in IMDM containing 50 μM 2-ME and M-CSF to generate
bone marrow-derived macrophages (BMDMs), or GM-CSF to generate
bone marrow-derived dendritic cells (BMDCs). Splenocytes were cul-
tured in RPMI 1640 medium containing 2 mM glutamine and 50 μM
2-ME [25,26]. Mouse RAW 264.7 macrophages (ATCC) were cultured
in RPMI 1640 medium containing 2 mM glutamine [27]. Culture
media (Invitrogen) were supplemented with 10% heat-inactivated FCS
(Sigma-Aldrich), 100 UI/ml penicillin and 100 μg/ml streptomycin
(Invitrogen). Human whole blood assay was performed as previously
described [28].
Cells were exposed to Salmonella minnesota ultra pure lipopoly-
saccharide (LPS, List Biologicals Laboratories), N-palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-
[S]-lysyl-[S]-lysyl-[S]-lysine (Pam3CSK4, EMC microcollections),
CpG motif containing oligonucleotide 1826 (CpG) (Invivogen), or
heat-inactivated (56 °C for 2 h) Escherichia coli (E. coli) O18 and
Staphylococcus aureus (S. aureus) AW7. Octacalcium phosphate
crystals (OCT), a gift of Dr N. Busso (CHUV, Lausanne, Switzerland)
were prepared as described [29]. The sirtuin pharmacological in-
hibitors cambinol [23], sirtinol [30], EX-527 [31], AGK2 [32], AK-7
[32] and CHIC-35 [31] and DMSO (Sigma-Aldrich) were used at
concentrations giving b20% cell death after 18 h of culture to ex-
clude nonspeciﬁc toxic effect. Cell viability was assessed using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
cell proliferation and viability assay [33].2.3. Cytokine and NO measurements
TNF, IL-6, IL-1β and IFN-γ concentrations in cell culture superna-
tants or plasmaweremeasured using DuoSet ELISA kits (R&D Systems).
TNF and IL-6 produced by human whole blood and PBMCs were
measured using WEHI 164 cells (TNF) and 7TD1 cells (IL-6) [34]. NO
concentrations were measured using the Griess reagent [35]. Serial
dilutions of NaNO2 were used as a standard.
2.4. RNA analyses by real-time polymerase chain reaction
Total RNA was isolated with the RNeasy kit (QIAGEN), reverse
transcribed using the QuantiTect reverse transcription kit (QIAGEN)
and used for real-time PCR analyses using a 7500 FAST Real-Time
PCR System (Applied Biosystems) as described [36]. Primer pairs are
listed in Supplementary Table 1. Ampliﬁcations with the 7500 Fast
mode consisted of forty cycles of 3 second denaturation step at 95 °C
and 30 second annealing/extension step at 60 °C. Samples were tested
in duplicates. Gene speciﬁc expression was normalized to an endoge-
nous control (GAPDHor hypoxanthine guanine phosphoribosyl transfer-
ase, HPRT) and expressed in arbitrary units relative to the expression in
untreated cells.
2.5. Flow cytometry
Cells were incubated 30 min at 4 °C in PBS containing 5 mM EDTA,
5% FCS, 2.4G2 monoclonal antibody (Fc-Block™, BD Biosciences) and
anti-mouse CD40 antibody (3/23-biotin revealed with CyChrome-
conjugated streptavidin, BD Biosciences). Flow cytometric analyses
were performed using a FACSCalibur™ ﬂow cytometer (BD Biosciences)
and data analyzed using FlowJo 8.8.6 software (FlowJow) [25,37].
2.6. Proliferation assay
The proliferation of splenocytes (1.5 × 105) cultured for 48 h in
96-well plates was assessed by measuring 3H-thymidine incorporation
over 18 h [25].
2.7. Impact of cambinol and sirtinol on the deacetylase activity of SIRT6
The deacetylase activity of recombinant SIRT6 incubated with in-
creasing concentrations of cambinol and sirtinol was determined using
theSIRT6ScreeningAssayKit fromAbcam, according to themanufacturer's
recommendations. Brieﬂy, recombinant sirtuin 6 was incubated for
45 min at 37 °C with cambinol or sirtinol, NAD+ and a peptide sub-
strate corresponding to amino acids 379–382 of human p53 conju-
gated to aminomethylcoumarin. The reaction was stopped with the
stop solution containing nicotinamide. Fluorescence was read with
excitation wavelength of 355 nm and measure wavelength of 460 nm.
Background ﬂuorescence was substracted to values. Percent activity
was calculated using the formula: % activity = (activity with inhibitor /
activity without inhibitor) × 100.
2.8. Western blot analyses
Nuclear and cytosolic protein extracts and total histones were
electrophoresed through SDS-polyacrylamide gels, transferred onto
nitrocellulose membranes and revealed as described previously [38–40].
Membranes were incubated with primary antibodies speciﬁc for total
and acetylated histone H4, ERK1/2, phospho-ERK1/2, p38, phospho-p38,
JNK, phospho-JNK, phospho-MEK1/2, phospho-MEK4 (Cell Signaling
Technology), actin, NF-κB p65 (Santa Cruz Biotechnology) and tubu-
lin (Sigma-Aldrich), then with a secondary horseradish peroxidase-
conjugated antibody (Sigma-Aldrich) [41]. Blots were revealed with
the enhanced chemiluminescence (ECL) Western blotting system (GE
Healthcare). Images were recorded using a LAS4000 system (Fujiﬁlm).
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RAW 264.7 macrophages (at 30% conﬂuence in 24-well plates) were
transfected with 600 ng of a AP-1 luciferase reporter vector together
with 60 ng of the Renilla pRL-TK vector (Promega) using the Fugene 6
transfection reagent (Roche Applied Sciences). Cells were pre-incubated
1 h with or without cambinol (50 μM) and then exposed for 18 h to
LPS (10 ng/ml). Luciferase andRenilla luciferase activitieswere quantiﬁed
using the Dual-Luciferase Reporter Assay System (Promega). Results
were expressed as the ratio of luciferase activity to Renilla luciferase
activity [42,43].
2.10. Growth of Klebsiella pneumoniae in vitro
Klebsiella pneumoniae Caroli (K. pneumoniae) was cultured over-
night at 37 °C in Luria–Bertani (LB) broth (BD biosciences). The follow-
ing day, 40 μl of the bacterial suspension was diluted 100-fold in LB
broth containing 0, 3.1, 12.5, 50 or 200 μM cambinol and incubated at
37 °C under agitation. Optical density was recorded at 640 nm.
2.11. In vivo models
To induce endotoxemia, mice were injected i.p. with 350 μg LPS.
Cambinol (10 mg/kg i.p.) was injected 1 h before and 24 h after LPS
challenge. To induce lethal sepsis, mice were injected intra-nasally
with 20–60 CFU of K. pneumoniae. Mice were treated with cambinol
(10 mg/kg i.p.) or vehicle three consecutive days starting 24 h before
bacterial challenge. Blood was collected to quantify TNF and circulating
bacteria. Body weight, severity scores and survival were registered at
least once daily [26].
2.12. Statistical analyses
Comparisons between the different groupswere performed by anal-
ysis of variance followed by the Fisher's exact test for categorical data
and the Mann–Whitney tests for continuous variables. The Kaplan–
Meier method was used for survival and differences were analyzed by
the log-rank sum test. All analyses were performed using PRISM
(GraphPad Software). P values are two-sided, and values b 0.05 were
considered to indicate statistical signiﬁcance.
3. Results
3.1. Cambinol inhibits cell response to microbial stimulation
Bone marrow-derived macrophages (BMDMs) stimulated with mi-
crobial products recognized through TLR4 (LPS), TLR1/TLR2 (Pam3CSK4)
and TLR9 (CpG) or with bacteria sensed primarily through TLR4 (E. coli)
and TLR2 (S. aureus) produced large amounts of TNF, IL-6 and IL-12p40
(Fig. 1A–B and data not shown). Cambinol inhibited TNF, IL-6 and
IL-12p40 secretion in a dose-dependent manner. Percent inhibition of
cytokine release ranged from 75% to 98% using 50 μM cambinol, which
is close to cambinol's IC50 for SIRT1 (56 μM) and SIRT2 (59 μM) [23].
The inhibition of cytokine production was unlikely dependent from a
toxic effect of cambinol, as cell viability measured at 4 and 18 h was
>95% and>80%, respectively.Moreover, real-timePCR analyses revealed
that cambinol interfered with LPS- and Pam3CSK4-induced Tnf, Il6 and
Il12b gene expression (1, 4 and 18 h after stimulation; Fig. 1C–D andFig. 1. Cambinol inhibits cytokine production by macrophages exposed to microbial produ
before exposure for 4 h (A, C and D) or 18 h (B) to LPS (10 ng/ml), Pam3CSK4 (10 ng/ml), C
trations in cell culture supernatants and Tnf and Il6 mRNA levels were quantiﬁed by ELISA
mRNA levels. Data are means ± SD of triplicate samples from one experiment representa
A.U.: arbitrary units. (E) BMDMs were pre-incubated for 1 h with or without cambinol (5
time-PCR and normalized to GAPDH mRNA levels. (F) BMDMs were primed 14 h with LP
exposed for 6 h with octacalcium phosphate crystals (OCP, 500 μg/ml). IL-1β concentrations
samples from one experiment. P b 0.05 for OCT plus cambinol versus OCT. A.U.: arbitrary udata not shown), suggesting that cambinol inhibits cytokine gene tran-
scription. Conﬁrming these results, cambinol also inhibited LPS-induced
Il1bmRNA upregulation and octacalcium phosphate crystals-mediated
IL-1β secretion (Fig. 1E–F). Upon infection, macrophages produce reac-
tive nitrogen species that are highly toxic for microorganisms and
upregulate CD40 co-stimulatorymolecules involved in cell–cell interac-
tions. NO is produced during the nitrosative burst by the inducible
NO synthase (iNOS, encoded by Nos2) [44]. In BMDMs, cambinol
dose-dependently inhibited Nos2 induction and NO production in re-
sponse to LPS, Pam3CSK4, CpG, E. coli and S. aureus (Fig. 2A–B). Further-
more, real-time PCR and ﬂow cytometry analyses showed that
cambinol inhibited the upregulation of Cd40 mRNA and CD40 receptor
(Fig. 2C–D).
We then analyzed the effects of cambinol on the response of bone
marrow-derived dendritic cells (BMDCs), splenocytes and humanwhole
blood and PBMCs to extend our observations beyond macrophages. As
observed with BMDMs, cambinol decreased the secretion of TNF, IL-6
and IL-12p40 and the upregulation of CD40 by BMDCs (Fig. 3A–B and
data not shown). Moreover, cambinol dose-dependently inhibited the
proliferation of splenocytes induced by toxic shock syndrome toxin-1
(TSST-1), staphylococcal enterotoxin B (SEB), LPS and Pam3CSK4
(Fig. 3C), and inhibited the production of IFN-γ by splenocytes exposed
to concanavalin A (Fig. 3D). Finally, cambinol markedly reduced TNF
and IL-6 levels in human whole blood (71–85% and 52–66% reduction
of TNF and IL-6 using 50 μM cambinol in two donors; Fig. 3E) and
PBMCs (data not shown) stimulatedwith LPS. Overall, these results indi-
cated that cambinol has powerful anti-inﬂammatory and immunosup-
pressive activity, interfering with the response of master regulators of
innate immune responses like macrophages and DCs.
3.2. Sirtinol inhibits cytokine production by macrophages; selective SIRT1
and SIRT2 inhibitors do not
To substantiate cambinol-mediated inhibition of cytokine production
by macrophages, we tested sirtinol, an inhibitor of SIRT1 and SIRT2
(IC50 SIRT1 = 131 μM; IC50 SIRT2 = 38 μM; Table 1) that shares with
cambinol a hydroxynaphthaldehyde type of structure [30,45,46]. Like
cambinol, sirtinol impaired TNF and IL-6 production by BMDMs stimu-
lated with LPS, Pam3CSK4, CpG ODN, E. coli and S. aureus (Fig. 4A–B and
data not shown). Moreover, sirtinol, as well as cambinol, inhibited the
production of TNF and IL-6 by RAW 264.7 macrophages, peritoneal mac-
rophages and human whole blood stimulated with LPS and Pam3CSK4
(Fig. 4C–D and data not shown).
To deﬁne whether inhibition of SIRT1 or SIRT2 alone have anti-
inﬂammatory effects, we used the selective SIRT1 inhibitors EX-
527 (IC50 SIRT1 = 0.1–1 μM; IC50 SIRT2 = 20–33 μM) and CHIC-35
(IC50 SIRT1 = 0.06–0.12 μM; IC50 SIRT2 = 2.8 μM), and the selective
SIRT2 inhibitors AGK2 (IC50 SIRT2 = 3.5 μM; IC50 SIRT1 > 50 μM) and
AK-7 (IC50 SIRT2 = 15.5 μM; IC50 SIRT1 > 50 μM) (Table 1) [31,32,45,47].
None of these inhibitors used over a large range of concentrations
(around 1/4, 1 and 4-fold the IC50s) inhibited LPS-induced upregulation
of Tnf, Il6 and Il12b mRNA (Fig. 5A) and TNF and IL-6 release by
BMDMs (Fig. 5B) and RAW 264.7 macrophages (data not shown).
Next, we thought to test whether dual inhibition of SIRT1 and SIRT2
was required to recapitulate the anti-inﬂammatory effects of cambinol
and sirtinol. For that purpose, we tested all possible combinations of
EX-527 or CHIC-35 with AGK2 or AK-7 at the concentrations reported
above (1/4, 1 and 4-fold IC50s). Unexpectedly, combined treatmentcts and bacteria. (A–D) BMDMs were pre-incubated for 1 h with or without cambinol
pG (2 μg/ml), E. coli (106 CFU/ml) and S. aureus (5x106 CFU/ml). TNF and IL-6 concen-
(A, B) and real time-PCR (C, D). Tnf and Il6 mRNA levels were normalized to GAPDH
tive of 2 to 4 experiments. P b 0.05 for all concentrations of cambinol versus control.
0 μM) before exposure to LPS (10 ng/ml). Il1b mRNA levels were quantiﬁed by real
S (100 ng/ml), washed, pre-incubated for 1 h with or without cambinol (50 μM) and
in cell culture supernatants were quantiﬁed by ELISA. Data are means ± SD of triplicate
nits.
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by BMDMs and RAW 264.7 macrophages. Indeed, as illustrated in
Fig. 6A–B, LPS-stimulated BMDMs exposed to EX-527 plus AGK2 or
CHIC-35 plus AK-7 produced normal or supra-normal levels of TNF. In
line with these observations, EX-527 at concentrations inhibiting both0
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of histone H4 similar to cambinol (Fig. 6E).
Considering that SIRT6 has been reported to promote cytokine
production by innate immune cells [16,21], we questioned whether
cambinol and sirtinol mediated their effects by targeting SIRT6 activ-
ity. Therefore, we quantiﬁed the deacetylase activity of recombinant
SIRT6 incubated in the presence of increasing concentrations of
cambinol and sirtinol. As shown in Fig. 6F, cambinol and sirtinol
used at concentrations able to inhibit cytokine production by macro-
phages (Fig. 1) did not reduce the enzymatic activity of SIRT6. Thus,
cambinol and sirtinol inhibit SIRT1, SIRT2 and other targets that are
neither SIRT3 nor SIRT6 ([48] and present data).
Altogether, these data suggested that cambinol and sirtinol inhibit
microbial product-induced cytokine production through targeting
more than just SIRT1 and SIRT2. They also strongly advocated pursu-
ing the development of hydroxynaphthaldehyde type of inhibitors as
efﬁcient anti-inﬂammatory compounds.
3.3. Inﬂuence of cambinol on the expression of sirtuins and pattern
recognition receptors
Considering the above results, we analyzed whether cambinol
inﬂuenced sirtuin expression. We ﬁrst measured by real-time PCR
the expression of Sirt1-7 in BMDMs exposed for 0, 1, 4 and 18 h to
LPS. Resting BMDMs expressed predominantly Sirt2, 4-6-fold less
Sirt1 and Sirt7, and 15-85-fold less Sirt4-Sirt6 (Fig. 7A). LPS increased
2-fold Sirt1 mRNA at 4 h and 2-7-fold Sirt2-Sirt7 mRNA at 18 h
(Fig. 7B). Cambinol modestly impaired LPS-induced Sirt1 (4 h) and
Sirt5 (18 h) mRNA upregulation, and slightly increased Sirt3 (18 h)and Sirt7 (4 h) mRNA expression (Fig. 7B). Western blot analyses
conﬁrmed these results, showing that LPS faintly increased SIRT1
and SIRT2 protein levels (SIRT1: 1.3-fold, SIRT2: 3.0-fold, t = 18 h)
and that cambinol had almost no additional effect on the expression
of SIRT1 and SIRT2 (Fig. 7C). Thus, cambinol does not mediate its
effects by modulating sirtuin expression.
We then questioned whether cambinol impaired innate immune
responses by targeting the expression of pattern recognition receptors
involved in the sensing of LPS (Tlr4, Cd14, and Md2), Pam3CSK4 (Tlr1,
Tlr2, and Cd36), CpG ODN (Tlr9), OCT crystals (Nlrp3: NLR family,
pyrin domain containing 3) and bacteria (Msr1:macrophage scavenger
receptor 1/CD204; and Itgax: integrinαX/CD11c). Real-time PCR analy-
ses revealed that cambinol (50 μM) inhibited LPS-mediated early
upregulation of Nlrp3 (79% reduction at 4 h) and late upregulation of
Tlr1, Tlr2 and Md2 (30–59% reduction at 18 h). In contrast, cambinol
did not modify the expression of Tlr4, Tlr6, Cd36, Clec7a (encoding for
dectin-1), Msr1, Itgax and Itgb2 (integrinβ2/CD18) and increased Tlr9
and Cd14 (Fig. 7D and data not shown). Hence, the early on inhibition
of Tnf, Il1b, Il6, Il12b, Cd40 and iNos gene expression by cambinol
(Figs. 1 and 2) unlikely resulted from an effect on the expression of
pattern recognition receptors. Considering that Nlrp3 has to be induced
to generate a functional inﬂammasome in macrophages [49], inhibition
of Nlrp3 expression by cambinol may play a role in bluntingmaturation
and secretion of IL-1β (Fig. 1F).
3.4. Cambinol impairs MAPK signaling
The sensing of microbial products through TLRs initiates intracellular
signaling leading to the activation of ERK1/2, p38 and JNK MAPKs and
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1503J. Lugrin et al. / Biochimica et Biophysica Acta 1833 (2013) 1498–1510NF-κB andAP-1 transcription factorswhich control the transcriptional ac-
tivation of immune genes [1]. We examined whether cambinol affected
signal transduction in macrophages. Interestingly, cambinol strongly
interfered with LPS-induced phosphorylation of ERK1/2, p38 and JNKTable 1
IC50 (in μM) of the inhibitors used in this study.
SIRT1 SIRT2 SIRT3 SIRT4
Cambinol 56 59 No inhibition Not tested
Sirtinol 37.6–131 38–58 >50 ?
EX-527 0.1–1 20–33 49 ?
AGK2 >50 3.5 >50 Not tested
AK-7 >50 15.5 >50 Not tested
CHIC-35 0.06–0.12 2.8 No inhibition ?
IC50s deﬁned in vitro are expressed in μM [30–32,45–47].
?: Not mentioned in studies testing these drugs (probably not tested).
⁎ Data obtained in this study.MAPKs, whereas it barely affected NF-κB p65 nuclear translocation
(Fig. 8A). In agreement, cambinol impaired LPS-induced AP-1-
mediated transcriptional activity in macrophages transfected with
an AP1-responsive luciferase construct (Fig. 8B). The phosphorylationSIRT5 SIRT6 SIRT7
42% inhibition at 300 μM No inhibition up to 250 μM⁎ Not tested
? No inhibition up to 62.5 μM⁎ ?
No inhibition ? ?
Not tested Not tested Not tested
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? ? ?
03
6
9
12
0
3
6
9
12
15
0
3
6
9
12
15
18
0
3
6
9
12
15
TN
F 
(ng
/m
l)
Cambinol
(μM) 
LPS 
0 12.5 50 200 0 
- Pam3CSK4 
0 12.5 50 200 0 
- 
A 
0
1
2
3
0
2
4
6
8
0
3
6
9
0
4
8
12
16
Sirtinol
(μM) 
LPS 
0 9.4 38 150 0 
- Pam3CSK4 
0 9.4 38 150 0 
- LPS 
0 9.4 38 150 0 
- Pam3CSK4 
0 9.4 38 150 0 
- 
TN
F 
(ng
/m
l)
IL
-6
 (n
g/m
l)
B 
C D 
IL
-6
 (n
g/m
l)
Pam3CSK4 
0 9.4 38 150 0 
- LPS
0 9.4 38 150 0 
- 
Sirtinol
(μM) 
Sirtinol
(μM) 
Fig. 4. Sirtinol inhibits cytokine production by macrophages. BMDMs (A–B) and RAW 264.7 macrophages (C–D) were pre-incubated for 1 h with or without sirtinol and cambinol
before exposure for 4 h (A, C) or 18 h (B, D) to LPS (10 ng/ml) and Pam3CSK4 (10 ng/ml). Concentrations of TNF and IL-6 in cell culture supernatants were quantiﬁed by ELISA. Data
are means ± SD of triplicate samples from one experiment representative of 2 experiments. P b 0.05 for all concentrations of sirtinol and cambinol versus control.
1504 J. Lugrin et al. / Biochimica et Biophysica Acta 1833 (2013) 1498–1510of MAPKs is catalyzed by MEKs (MAP2Ks) that are quickly activated fol-
lowing microbial sensing. Western blot analyses revealed that cambinol
inhibited LPS-mediated phosphorylation of MEK1/2 (upstream ERK1/2)
at 15 min and phosphorylation of MEK4 (upstream JNK and p38) at
15–60 min (Fig. 8C). These observations suggested that cambinol inter-
feres with inﬂammatory responses at least in part through inhibiting
MAPK and MEK activation.m
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intraperitoneally). Administration of cambinol signiﬁcantly reduced
TNF circulating levels (1.5-fold, P = 0.04, Fig. 9A) and remarkably
increased survival from 8% to 46% (P b 0.001, Fig. 9B). To further
substantiate the concept of immunomodulation by cambinol as a
treatment strategy for severe sepsis, we tested cambinol in an exper-
imental model of lethal, acute K. pneumoniae pneumonia. Cambinol
increased survival from 13% to 60% (P = 0.013, Fig. 9C), which was
associated with a trend towards reduced bacterial burden in the
lungs (median counts: 170 versus 5800 CFU/lung in cambinol versus
DMSO treated mice; P = 0.3). Importantly, cambinol had no direct
toxic effect on K. pneumonia in vitro (Fig. 9D).
4. Discussion
HDAC inhibitors have been widely studied in the ﬁeld of cancer;
their inﬂuence on the innate immune system is less well characterized.
This is particularly true for inhibitors of sirtuins, which were developed
more recently than inhibitors of classical HDACs (HDAC1-11). Here, we
report that cambinol, a compound that inhibits the deacetylase activityof SIRT1 and SIRT2 [23], powerfully inhibits inﬂammatory and innate
immune responses in vitro and in vivo. Importantly, cambinol protects
mice from lethal endotoxic and septic shock. In line with our results,
reducing the bioavailability of the sirtuin's co-factor NAD+ through
inhibition or deletion of the nicotinamide phosphoribosyltransferase
(Nampt) decreased TNF and IFN-γ secretion by PHA-stimulated periph-
eral blood lymphocytes and TNF production in mice challenged with
LPS [16,21,52]. These observations could argue for a role of sirtuins
in the regulation of innate immune gene expression and in host defen-
sive responses against microbial infections. Yet, as discussed below,
cambinol acts probably by targeting more than just SIRT1 and SIRT2.
Inhibitors of classical HDACs impair numerous facets of inﬂamma-
tory and innate immune responses and have shown great efﬁcacy
in models of inﬂammatory and autoimmune diseases such as colitis,
arthritis, graft-versus host disease, lupus and atherosclerosis to cite
only a few (reviewed in [6]). More recently, we reported a proof of
concept study showing that such inhibitors also protect from toxic
shock and septic shock [25,53]. To which extent members of different
HDAC subfamilies (i.e. HDACs versus SIRTs) play a redundant or a
complementary role in the regulation of immune responses is still
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1506 J. Lugrin et al. / Biochimica et Biophysica Acta 1833 (2013) 1498–1510largely unknown. The observation that HDAC and SIRT knockout ani-
mals display speciﬁc phenotypes strongly advocates non-redundant
roles of these enzymes in vivo (reviewed in [4,54]). Furthermore, a
common phenotype may arise from multiple mechanisms. For exam-
ple, HDAC6, HDAC9 and SIRT1 all target forkhead box P3 (Foxp3), and
therapeutic inhibition of HDAC6, HDAC9 or SIRT1 increased Foxp3
gene expression and the function of regulatory T cells [55,56]. Where-
as HDAC6 inhibition enhanced Treg function through the induction
of the heat shock response, loss of HDAC9 and SIRT1 increased
Foxp3 expression through the acetylation and the stabilization of
STAT5 and p65, respectively [57]. From pharmacologic and biological
points of view, it will be interesting to deﬁne whether inhibitors of
HDAC1-11 and sirtuins have additional or synergistic effects on cytokine
production and immune responses, as recently reported for the pro-
apoptotic activity of HDAC1-11 and sirtuin inhibitors towards human
leukemia cells [58].
In agreement with strong inhibition of cytokine production,
cambinol impaired the phosphorylation of ERK1/2, p38 and JNK, and
of the upstreamMAPK kinases in LPS-stimulated macrophages. Our re-
sults are in line with studies showing that sirtinol blocked epidermal
growth factor (EGF) and insulin-like growth factor-I (IGF-I)-inducedphosphorylation of ERK1/2, p38 and JNK in human breast and lung can-
cer cells [59] and reduced Ras activation as well as ERK1/2 phosphory-
lation in rat neurons [60]. Further supporting the concept of MAPK
targeting by sirtuin inhibitors, the pan-sirtuin inhibitor nicotinamide
impaired MAPK activation (primarily ERK1/2) upon BCR engagement
in primary B cells [61]. On the contrary, there was no discernible reduc-
tion of MAPK phosphorylation in TNF-stimulated macrophages from
myeloid conditional SIRT1 knockout mice [11]. Sirtuin inhibition also
did not affect MAPK phosphorylation in LPS-treated J774 macrophages,
which may be due to the fact that LPS poorly increased p38 MAPK only
in these cells [17]. Moreover, SIRT1 has been shown to deacetylate c-Jun
and c-Fos that are the principal components of the AP-1 transcription
factor [62–64]. Differences in strategies used to target sirtuins (inhibi-
tors versus knockout), stimuli and cell types may underlie these
discrepancies.
MAPK phosphatases (MKPs) belong to the family of dual-speciﬁcity
phosphatases (Dusps). The ten functional MKPs (Dusp1, Dusp2, Dusp4-
10 and Dusp16) are integral components of the negative feedback loop
regulating MAPK activity [65,66], opening the possibility that cambinol
inhibited the MAPK pathway via MKPs. Indeed, pharmacological
inhibition of classical HDACs enhanced MKP1 (Dusp1) acetylation
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1508 J. Lugrin et al. / Biochimica et Biophysica Acta 1833 (2013) 1498–1510and MKP1-mediated de-phosphorylation of p38, thus interrupting
p38 signaling in macrophages [67]. Moreover, SIRT1 was shown to
repress MKP3 (Dusp6) expression, thereby increasing N-Myc phos-
phorylation and activity in neuroblastoma [68], and to inhibit pro-
tein tyrosine phosphatase 1B (PTP1B) in chondrocytes, myoblasts
and liver [69,70]. Yet, we have not detected an inﬂuence of cambinol
on MKP expression in macrophages (data not shown).
The role of sirtuins in inﬂammatory and immune responses has
been addressed mainly for SIRT1, more rarely for SIRT6, leading to
controversial conclusions [11–22]. Numerous studies have dissected
at the molecular level the negative regulation of AP-1 and NF-κB
activities by SIRT1 (reviewed in [71,72]). In agreement, SIRT1 was
shown to protect from lung inﬂammation, chronic obstructive pulmo-
nary disease, experimental autoimmune encephalomyelitis, hepatic
steatosis, insulin insensitivity, and inﬂammatory function of macro-
phages [11,12,14,63,73,74]. Yet, and in marked contrast, SIRT1 has also
been involved in the pathogenesis of lupus, experimental autoimmune
encephalomyelitis, collagen-induced arthritis, allergic airway disease,
trauma–hemorrhage, allograft rejection and psoriasis [18–20,74–78].
Other studies suggested that SIRT1 and SIRT6 promote rather than in-
hibit inﬂammatory responses. For instance, SIRT1 stimulated HIF-2α
transactivation capacity during hypoxia [79], antagonized the develop-
ment and the function of Treg cells [55–57] and regulated autophagy,
an important arm of innate and adaptive immune responses [80,81].
Likewise, SIRT6 was required for optimal cytokine synthesis by macro-
phages, DCs and lymphocytes [16,21]. As mentioned above, differences
in experimental approaches, especially the usage of sirtuin activators
and inhibitors or the inhibition of sirtuin expression using small interfer-
ing RNA, short hairpin RNA and knockout animals, may explain these
divergences. Importantly, targeting several sirtuins (and maybe other
uncharacterized targets) with inhibitors such as cambinol, sirtinol or
nicotinamide may have different outcomes than targeting one speciﬁc
sirtuin using isoform-speciﬁc inhibitors, siRNA/shRNA or knockout
approaches. As a good example, targeting SIRT1 and SIRT2, but not
SIRT1 or SIRT2, was necessary to induce p53 acetylation and cell death
[82], indicating that sirtuins may work in concert to develop some of
their biological effects. Selective inhibitors of SIRT1 (EX-527 and CHIC-
35) and SIRT2 (AGK2 and AK-7) used either alone or in combination
and EX-527 used at concentrations inhibiting both SIRT1 and SIRT2
had no inhibitory effect on cytokine production by macrophages. SIRT6
has been shown to promote cytokine production by innate immune
cells [16,21], and was thus a potential target of cambinol and sirtinol.
Yet, neither cambinol nor sirtinol inhibited SIRT6 deacetylase activity
in vitro at concentrations reported to inhibit cytokine production by
macrophages. Thus, we speculate that, apart from SIRT1 and SIRT2,
cambinol and sirtinol target enzymes which are not SIRT3 and SIRT6
[48], and possibly not sirtuins.
Our observations that cambinol powerfully inhibits the produc-
tion of pro-inﬂammatory cytokines induced by microbial products
and bacteria in macrophages, DCs and splenocytes are in full agree-
ment with the efﬁcient protection afforded by cambinol during
toxic shock and septic shock. Our results strengthen the develop-
ment of inhibitors with increased speciﬁcity and activity in order to
minimize possible undesirable side effects of the drug. Overall, our
data suggest that pharmacological inhibitors structurally related
to cambinol have promising therapeutic potential for the treatment
of pathologies characterized by acute and chronic inﬂammatory
responses.
Supplementary data to this article can be found online at http://
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